BRAF and neoplasm: The oncogenic driver BRAF mutation, present in nearly 50% of melanomas—mostly young patients— has been described as inducing changes that facilitate tumor immune escape by the production of immunosuppressive cytokines, down regulation of Major Histocompatibility Complex I (MHC I) and recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [11,12,13].